Actively Recruiting
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
Led by AdventHealth Translational Research Institute · Updated on 2026-04-17
12
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how exercise affects the amount of glucose produced by the liver in people both with and without Type 2 diabetes (T2D) and fatty liver disease (hepatic steatosis). This study aims to better understand blood sugar control and liver fat treatment by comparing these two groups. Participants are divided into two groups: a control group of lean, healthy individuals and a group with T2D and elevated liver fat. The study includes several assessments such as measuring liver fat using magnetic resonance imaging, fitness testing with a bike exercise, and body composition analysis by DEXA scan. These tests help evaluate the effects of exercise on glucose production and liver health. During the study, participants will undergo detailed evaluations including imaging, fitness tests, and glucose production measurements on Day 14. Researchers will monitor and compare these results between the groups to understand how exercise influences glucose production. The study runs from April 2025 to April 2026, with participants closely followed during this time to collect all necessary data.
CONDITIONS
Brief Title
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form
- Willingness to comply with all study procedures and availability for the study duration
- Male or pre-menopausal female aged 25 to 55 years
- For T2D group: BMI between 25 and 45 kg/m2, sedentary (1 day or less of structured exercise per week), HbA1c 67.5%, liver fat 65.6% by MRI, weight stable within �b12 kg for prior 3 months
- For healthy controls: BMI between 18.5 and 27.5 kg/m2, active (3 or more days of structured exercise per week), normal liver fat by FibroScan and MRI, weight stable within �b12 kg for prior 3 months
You will not qualify if you...
- Current use of insulin, incretin mimetics, or thiazolidinediones
- Recent change in glucose-lowering medications within 3 months
- Unable to stop medications interfering with glucose metabolism during key visits
- Resting blood pressure 60 160/100 mm Hg
- Triglycerides 60 500 mg/dL
- Any serious renal, cardiac, liver, lung, neurological disease or unstable medical condition
- Clinically significant ECG abnormalities contraindicating exercise
- Active cancer except basal cell carcinoma
- Pregnancy, lactating, planned pregnancy, post- or peri-menopausal women, or hysterectomy
- Use of drugs affecting energy metabolism or body weight
- Thyroid disorders not stable or treated
- Current blood thinners or beta-blocker use
- Recent major surgery or bariatric surgery
- Anemia or recent blood transfusion/donation
- Current smokers or recent tobacco use
- Drug or alcohol abuse or positive toxicology
- Excessive alcohol consumption or binge drinking history
- Metal implants or inability to tolerate MRI
- Psychiatric conditions preventing protocol adherence
- Active infections needing treatment or certain viral infections
- Inability or unwillingness to communicate or provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 weeks
Participants undergo assessments including magnetic resonance liver imaging, cycle ergometer fitness testing, and body composition measurements.
1 to 3 visits depending on assessments
Duration - 14 days
Participants are observed to assess endogenous glucose production and glycemic control.
Assessments on Day 14
Trial Site Locations
Total: 1 location
1
AdventHealth Translational Research Institute
Orlando, Florida, United States, 32804
Actively Recruiting
Research Team
R
Recruitment Department
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here